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Incidence of type 2 diabetes after bariatric surgery: 
population-based matched cohort study
Helen Booth, Omar Khan, Toby Prevost, Marcus Red dy, Alex Dregan, Judith Charlton, Mark Ashworth, Caroline Rudisill, Peter Littlejohns, 
Martin C Gulliford
Summary
Background The eﬀ ect of currently used bariatric surgical procedures on the development of diabetes in obese people 
is not well deﬁ ned. We aimed to assess the eﬀ ect of bariatric surgery on development of type 2 diabetes in a large 
population of obese individuals.
Methods We did a matched cohort study of adults (age 20–100 years) identiﬁ ed from a UK-wide database of family 
practices, who were obese (BMI ≥30 kg/m²) and did not have diabetes. We enrolled 2167 patients who had undergone 
bariatric surgery between Jan 1, 2002, and April 30, 2014, and matched them—according to BMI, age, sex, index year, 
and HbA1c—with 2167 controls who had not had surgery. Procedures included laparoscopic gastric banding (n=1053), 
gastric bypass (795), and sleeve gastrectomy (317), with two procedures undeﬁ ned. The primary outcome was 
development of clinical diabetes, which we extracted from electronic health records. Analyses were adjusted for 
matching variables, comorbidity, cardiovascular risk factors, and use of antihypertensive and lipid-lowering drugs.
Findings During a maximum of 7 years of follow-up (median 2·8 years [IQR 1·3–4·5]), 38 new diagnoses of diabetes 
were made in bariatric surgery patients and 177 were made in controls. By the end of 7 years of follow-up, 4·3% 
(95% CI 2·9–6·5) of bariatric surgery patients and 16·2% (13·3–19·6) of matched controls had developed diabetes. 
The incidence of diabetes diagnosis was 28·2 (95% CI 24·4–32·7) per 1000 person-years in controls and 5·7 (4·2–7·8) 
per 1000 person-years in bariatric surgery patients; the adjusted hazard ratio was 0·20 (95% CI 0·13–0·30, p<0·0001). 
This estimate was robust after varying the comparison group in sensitivity analyses, excluding gestational diabetes, or 
allowing for competing mortality risk.
Interpretation Bariatric surgery is associated with reduced incidence of clinical diabetes in obese participants without 
diabetes at baseline for up to 7 years after the procedure.
Funding UK National Institute for Health Research.
Copyright © Booth et al. Open Access article distributed under the terms of CC BY.
Introduction
Obesity is an increasing worldwide health problem.1 
Treatment of obesity with lifestyle or behavioural 
approaches is generally associated with only small 
reductions in bodyweight that are typically not sustained.2,3 
Bariatric surgical interventions for obesity have been 
associated with substantial weight loss, decreased 
morbidity, and improvements in quality of life.4,5 Despite 
the escalating use of bariatric surgery,6 the evidence base 
supporting use of these procedures for obesity and 
obesity-associated morbidity is scant. In a systematic 
review,7 only 11 high-quality trials were identiﬁ ed (with 
796 participants). Similarly, little evidence is available on 
the long-term eﬀ ects of bariatric surgery. The Swedish 
Obese Subjects (SOS) study,8 which provides the best 
evidence for long-term eﬀ ects so far, was initiated more 
than 20 years ago and the surgical procedures used might 
not reﬂ ect current practice. Most reported studies have 
been done in specialist centres and outcomes achieved 
might not be typical of routine practice.
The possible eﬀ ect of bariatric surgery on type 2 
diabetes is of particular importance because 3% of 
severely obese individuals develop diabetes every year.9 
Data show that bariatric surgery might contribute to 
resolution of existing type 2 diabetes.10,11 Evidence is 
scarcer for whether bariatric surgery for weight loss in 
obese patients without diabetes prevents future 
development of diabetes. In the SOS study,9 1658 patients 
without diabetes were followed up over a 15-year period, 
with a 76% reduction in the incidence of diabetes after 
bariatric surgery. However, most participants in the 
SOS study had vertical banded gastroplasty—an 
operation that is not undertaken widely nowadays 
because of the high frequency of weight regain.
Participants in research studies often undergo intensive 
follow-up that might not be typical of care provided in 
routine clinical practice. The aim of our study was to 
recruit a population-based cohort of patients and 
matched controls, drawn from a database of primary care 
electronic health records, to provide a pragmatic 
assessment of the eﬀ ect of bariatric surgery on the 
development of clinical diabetes in obese individuals 
receiving routine clinical care.
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Methods
Participants
We selected participants from the Clinical Practice 
Research Datalink (CPRD). This database includes 
electronic health records for more than 5 million 
individuals currently registered for primary care at more 
than 680 family practices in the UK.12 The size and 
geographical distribution of family practices, and the age 
and sex of individuals included in the database, are broadly 
representative of the UK population, enabling selection of 
population-based controls. The high quality of CPRD 
diagnostic and prescription information has been reported 
elsewhere.13
From the CPRD database we identiﬁ ed a cohort of 
obese individuals without diabetes who had undergone 
bariatric surgery before April 30, 2014, using medical 
codes for laparoscopic gastric banding, gastric bypass, or 
sleeve gastrectomy. We deﬁ ned the date on which the 
ﬁ rst code was recorded as the index date. We excluded 
participants who had bariatric surgery less than 1 year 
after the start of the electronic health record, because this 
record might have indicated a procedure undertaken 
before their registration at the family practice. We also 
excluded patients younger than 20 years at the index 
date, those with either no BMI record before surgery or a 
last recorded BMI value less than 30 kg/m², individuals 
with a record for gastric band removal before the index 
date, and patients with diabetes diagnosed on or before 
the index date. The most recent BMI value was not 
always recorded immediately before surgery and might 
not have provided an accurate assessment of the degree 
of preoperative obesity.
We obtained matched controls for comparison from a 
cohort of 103 502 obese individuals without diabetes, 
sampled from the CPRD, who did not have bariatric 
surgery and were not older than the maximum age of the 
bariatric surgery patients. We deﬁ ned the index date 
for controls as the date of the earliest BMI record on 
which the patient attained their highest BMI category. 
We matched controls for age, BMI, sex, index year, and 
highest measured HbA1c category (<6%, 6·0% to <6·5%, 
and not known). We did nearest neighbour matching 
without replacement14 using the psmatch2 command in 
Stata version 13 (College Station, TX, USA).
We analysed data that were fully anonymised. The 
CPRD Independent Scientiﬁ c Advisory Committee gave 
scientiﬁ c and ethics approval for the study (ISAC 13_089).
Procedures
We recorded baseline characteristics of bariatric surgery 
patients and matched controls. We identiﬁ ed new 
diagnoses of clinical diabetes from prospective electronic 
health records, obtaining data for medical diagnoses, 
drug prescriptions, and HbA1c values. We judged patients 
to have a diagnosis of clinical diabetes if a medical code 
for diabetes was recorded, if insulin or oral hypoglycaemic 
drugs were prescribed, or if an HbA1c value of 6·5% or 
higher was recorded (WHO criteria).15 Oral hypoglycaemic 
drugs included sulfonylureas, metformin, acarbose, 
dipeptidyl-peptidase-4 inhibitors, glitazones, and glinide 
drugs. We coded women with recorded diagnoses of 
polycystic ovary syndrome, who were prescribed diabetes 
drugs but were never diagnosed with diabetes, as non-
diabetic. We took the date of the earliest medical, 
therapeutic, or test event as the date of diabetes diagnosis. 
We included all new diagnoses of diabetes because 
diﬀ erent diabetes phenotypes cannot always be 
distinguished clearly in clinical practice. However, we 
analysed new cases of diabetes according to codes for 
type 1 diabetes, for prescription of insulin within 
6 months of the diagnosis date, and for diagnoses of 
gestational diabetes.
The index BMI was the most recently recorded value 
before the index date. We identiﬁ ed records for smoking 
status, blood pressure, and cholesterol and used the most 
recently recorded value before the index date for the 
baseline value. We identiﬁ ed concomitant depression, 
coronary heart disease, and stroke with medical codes.16–18
Statistical analysis
To assess diabetes onset, we used a time-to-event 
framework, using a Cox proportional hazards model. 
We classed failure as a new diagnosis of diabetes. 
We censored records at the end of a participant’s 
registration, the last date of CPRD data collection, or 
death, and we censored follow-up after 7 years when only 
a few participants remained. We adjusted models for: 
matching variables (age, sex, BMI, HbA1c, and index 
year); prevalent coronary heart disease, stroke, and 
previous diagnosis of depression; smoking status; total 
cholesterol greater than 5 mmol/L; blood pressure higher 
than 140/90 mm Hg; and use of statins and anti-
hypertensive drugs before surgery. Quadratic terms for 
age and BMI did not improve goodness of ﬁ t. We used 
indicator variables for missing data for blood pressure 
and cholesterol. We evaluated the proportional hazards 
assumption with no evidence that it was violated. To allow 
for clustering of responses by family practice, we used 
robust variance estimates.
We did several sensitivity analyses. We used the 
unmatched cohort of 103 502 obese patients without 
diabetes for comparison. Using the matched cohort, 
we excluded participants diagnosed with diabetes within 
12 months of the index date, then we excluded patients 
diagnosed with gestational diabetes. We also assessed the 
eﬀ ect of competing risk on mortality.19 We used 
Stata version 13 for all analyses.
Role of the funding source
The funder had no role in study design, data collection, 
data analysis, data interpretation, or writing of the report. 
The corresponding author had full access to all the data 
in the study and had ﬁ nal responsibility for the decision 
to submit for publication.
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Results
Between Jan 1, 2002, and April 30, 2014, 4793 obese 
patients in the CPRD database had undergone bariatric 
surgery. We excluded 1324 individuals whose procedure 
was ﬁ rst recorded less than 1 year after the start of their 
electronic health record, 14 people younger than 20 years 
at the index date, and 401 patients with either no BMI 
record before surgery or BMI values lower than 30 kg/m² 
before surgery. A further 878 people were excluded who 
had a diagnosis of diabetes before the date of their 
surgery, and nine individuals were excluded who 
underwent gastric band removal before the index date. 
Therefore, we included 2167 obese patients without 
diabetes who had bariatric surgery. We matched these 
patients according to age, BMI, sex, index year, and HbA1c 
category with 2167 controls who did not have surgery. 
Median duration of follow-up was 2·8 years (IQR 1·3–4·5), 
with a maximum of 7 years of follow-up.
The type of bariatric surgery was classiﬁ ed according to 
the procedure recorded on the index date. 1053 (49%) 
patients received laparoscopic gastric banding, 795 (37%) 
had gastric bypass procedures, and 317 (15%) underwent 
sleeve gastrectomy; two people had codes for more than 
one type of procedure on the index date.
Baseline values were those most recently recorded 
before the index date (table 1). Bariatric surgery patients 
and controls were generally well matched for age, sex, 
and BMI; index BMI was 40 kg/m² or higher for about 
60% of all participants. 1198 (55%) bariatric surgery 
patients and 701 (32%) controls had previously been 
diagnosed with depression before the index date 
(p<0·0001). Bariatric surgery patients were more likely to 
have elevated blood pressure or raised total cholesterol 
values and to be treated with anti-hypertensive or lipid-
lowering drugs (table 1).
The ﬁ gure shows the incidence of diabetes in bariatric 
surgery patients during the 7 years after the procedure 
and in matched controls. 38 new diagnoses of diabetes 
were made in bariatric surgery patients and 177 were 
made in controls (table 2). None of the participants was 
recorded as having type 1 diabetes. Three controls and 
one bariatric surgery patient with diabetes were treated 
with insulin within 6 months of the diabetes diagnosis 
date. Ten controls and three bariatric surgery patients 
had gestational diabetes and were excluded in the 
sensitivity analysis. By the end of 7-year follow-up, 4·3% 
(95% CI 2·9–6·5) of bariatric surgery patients and 16·2% 
(13·3–19·6) of matched controls had developed diabetes 
(table 2). Incidence of diabetes was 28·2 (95% CI 
24·4–32·7) diagnoses per 1000 person-years in controls 
and 5·7 (4·2–7·8) per 1000 person-years in bariatric 
surgery patients (table 3).
Compared with controls, the unadjusted hazard ratio for 
development of diabetes in bariatric surgery patients was 
0·20 (95% CI 0·14–0·30; p<0·0001). Multivariable 
adjustment for baseline characteristics (including 
matching variables [ie, age, BMI, sex, index year, and HbA1c 
category]; comorbid cardiovascular disease and depression; 
smoking; and hypertension, high blood cholesterol, and 
associated treatment) had a negligible eﬀ ect on the size of 
Bariatric surgery 
patients (n=2167)
Matched controls 
(n=2167)
p value
Women 1812 (84%) 1878 (87%) Matched
Age (years) 44·4 (10·1) 44·6 (14·1) Matched
BMI (kg/m²) 43·0 (8·1) 43·2 (8·6) Matched
BMI category Matched
Obese (30–34·9 kg/m²) 339 (16%) 332 (15%) ..
Severe obesity (35–39·9 kg/m²) 535 (25%) 551 (24%) ..
Very severe obesity (≥40 kg/m²) 1293 (60%) 1284 (59%) ..
Index year Matched
2002–05 84 (4%) 113 (5%) ..
2006–08 483 (22%) 442 (20%) ..
2009–11 979 (45%) 1014 (47%) ..
2012–14 621 (29%) 598 (28%) ..
HbA1c category Matched
<6·0% (<42 mmol/mol) 208 (10%) 195 (9%) ..
6·0% to <6·5% (42 to <48 mmol/mol) 54 (2%) 50 (2%) ..
Not recorded 1905 (88%) 1922 (89%) ..
Coronary heart disease 60 (3%) 58 (3%) 0·847
Stroke 20 (1%) 26 (1%) 0·381
Previous depression diagnosis 1198 (55%) 701 (32%) <0·0001
Current smoker 372 (17%) 386 (18%) 0·590
Blood pressure recorded >140/90 mm Hg* 581 (27%) 464 (21%) 0·0002
Total cholesterol recorded >5 mmol/L* 845 (39%) 387 (18%) <0·0001
Treatment for hypertension 906 (42%) 519 (24%) <0·0001
Lipid-lowering treatment 270 (12%) 183 (8%) <0·0001
Data are number of people (%) or mean (SD). *591 (27%) controls and 18 (1%) bariatric surgery patients had missing 
values for blood pressure and 1466 (68%) controls and 557 (26%) bariatric surgery patients had missing values for 
cholesterol.
Table 1: Baseline characteristics
Figure: Incidence of type 2 diabetes in patients undergoing bariatric surgery and in matched controls during 
7 years of follow-up
Number at risk
Controls
Bariatric surgery
0
..
..
1
1847
1759
2
1317
1369
3
857
1017
4
558
692
5
358
440
6
238
264
7
132
154
Years since surgery
0
5
10
15
20
25
Pr
op
or
tio
n 
w
ith
 d
ia
be
te
s (
%
)
Controls 
Bariatric surgery
Articles
4 www.thelancet.com/diabetes-endocrinology   Published online November 3, 2014   http://dx.doi.org/10.1016/S2213-8587(14)70214-1
the estimated hazard ratio. The fully adjusted hazard ratio 
for bariatric surgery was 0·20 (0·13–0·30; p<0·0001). After 
allowing for bariatric surgery, baseline characteristics were 
generally not associated with the risk of developing 
diabetes, except for an increased hazard associated with 
raised baseline HbA1c (appendix p 1).
Table 3 shows the incidence of diabetes and hazard 
ratios for development of diabetes by subgroup. The eﬀ ect 
of bariatric surgery was generally similar in men and 
women and across age groups. No interaction was noted 
between bariatric surgery and age. The eﬀ ect of bariatric 
surgery was also similar for index periods between 2002 
and 2014, even though gastric banding accounted for 96% 
(81 of 84) of procedures in the earliest period and only 24% 
(148 of 621) in the latest. However, an interaction was 
noted between bariatric surgery and increasing BMI 
(p=0·0819). In the fully adjusted model, which included 
adjustment for index year and the other covariates, hazard 
ratios were slightly lower for both gastric bypass and 
sleeve gastrectomy compared with laparoscopic gastric 
banding (p=0·0714), although every type of procedure was 
associated with a lower incidence of diabetes compared 
with controls. Only a few patients were included in some 
subgroups: laparoscopic gastric banding was associated 
with 30 new diagnoses of diabetes, gastric bypass with six, 
and sleeve gastrectomy with two.
The association of bariatric surgery with decreased 
incidence of diabetes was robust in several sensitivity 
analyses. When the entire comparison cohort of 
103 502 obese individuals without diabetes was used for 
reference (rather than selected matched controls), the 
adjusted hazard ratio for the eﬀ ect of bariatric surgery on 
development of diabetes was 0·16 (95% CI 0·11–0·22; 
p<0·0001). Diagnosis of diabetes might be more likely 
soon after the index date because of heightened medical 
surveillance. However, when patients with diabetes 
diagnosed within the ﬁ rst year after the index date were 
excluded, the adjusted hazard ratio was 0·20 (0·12–0·32; 
p<0·0001). Exclusion of individuals who had gestational 
diabetes gave an adjusted hazard ratio of 0·19 (0·13–0·30; 
p<0·0001). In a competing risks analysis, allowing for 
the competing risk of death, the adjusted hazard ratio 
was 0·20 (0·13–0·31, p<0·0001). Analyses that used only 
clinical criteria (ie, medical diagnoses and drug 
prescriptions) and not HbA1c for diagnosis of diabetes 
gave similar results (data not shown).
Discussion
In a large population-based cohort of obese patients 
undergoing bariatric surgery by contemporary methods, 
the risk of developing type 2 diabetes was reduced by 
80% over a maximum of 7 years of follow-up compared 
with controls who did not undergo surgery. Our study is 
perhaps the ﬁ rst large-scale pragmatic study to assess the 
eﬀ ect of current bariatric surgical procedures on diabetes 
incidence in the context of usual care settings (panel). 
Even in patients seen in routine clinical practice, our 
results show that modern bariatric surgical procedures 
have particular eﬀ ectiveness for diabetes prevention in 
obese patients.
An eﬀ ect of bariatric surgery on incidence of diabetes 
was noted in both men and women and across all ages. 
Gastric bypass and sleeve gastrectomy were associated 
with slightly lower relative hazards for diabetes than was 
laparoscopic gastric banding, but we caution against 
Bariatric surgery patients Matched controls
Diabetes 
diagnoses 
(n)
Proportion with 
diabetes* 
(95% CI)
Diabetes 
diagnoses 
(n)
Proportion with 
diabetes* (95% CI)
Year
1 14 0·7% (0·4–1·2) 73 3·5% (2·8–4·4)
2 4 1·0% (0·6–1·5) 41 5·9% (5·0–7·1)
3 5 1·4% (0·9–2·1) 23 7·9% (6·7–9·3)
4 6 2·1% (1·4–3·0) 20 10·4% (8·8–12·2)
5 4 2·7% (1·9–4·0) 10 12·4% (10·5–14·7)
6 3 3·6% (2·4–5·2) 5 13·8% (11·6–16·3)
7 2 4·3% (2·9–6·5) 5 16·2% (13·3–19·6)
*Calculated from time-to-event data and not from aggregate ﬁ gures shown in 
columns to left.
Table 2: New diabetes diagnoses during up to 7 years of follow-up
Diabetes incidence per 1000 person-
years (95% CI)
Adjusted hazard 
ratio* (95% CI)
p value
Bariatric surgery 
patients
Controls
All participants 5·7 (4·2–7·8) 28·2 (24·4–32·7) 0·20 (0·13–0·30) <0·0001
Sex
Men 6·8 (3·2–14·3) 38·5 (26·7–55·4) 0·17 (0·06–0·46) 0·0004
Women 5·5 (3·9–7·8) 26·8 (22·8–31·5) 0·21 (0·13–0·33) <0·0001
Baseline BMI category (kg/m²)
30–34·9 6·1 (2·9–12·9) 15·7 (9·7–25·2) 0·39 (0·11–1·42) 0·1469
35–39·9 5·9 (3·2–10·9) 22·1 (16·0–30·5) 0·24 (0·12–0·49) <0·0001
≥40 5·5 (3·6–8·4) 35·0 (29·3–41·7) 0·15 (0·09–0·25) <0·0001
Age group (years)
20–34 1·7 (0·4–7·0) 17·3 (11·8–25·2) 0·14 (0·03–0·63) 0·0102
35–54 6·3 (4·4–9·3) 26·3 (21·1–32·7) 0·21 (0·13–0·34) <0·0001
≥55 7·0 (3·5–14·1) 42·1 (33·3–53·2) 0·18 (0·08–0·38) <0·0001
Type of procedure†
Laparoscopic gastric banding 7·3 (5·1–10·5) 24·9 (20·2–30·6) 0·29 (0·18–0·48) <0·0001
Gastric bypass 3·2 (1·4–7·1) 33·3 (26·0–42·7) 0·10 (0·04–0·25) <0·0001
Sleeve gastrectomy 2·9 (0·7–11·7) 31·7 (21·4–47·0) 0·07 (0·01–0·30) 0·0003
Index period
2002–05 3·8 (1·0–15·3) 29·7 (18·9–46·5) 0·12 (0·03–0·52) 0·0045
2006–08 8·3 (5·4–12·9) 25·8 (19·7–33·9) 0·32 (0·18–0·57) <0·0001
2009–11  4·2 (2·5–7·3) 28·2 (22·6–35·4) 0·14 (0·06–0·31) <0·0001
2012–14 4·4 (1·4–13·7) 32·4 (22·5–46·6) 0·10 (0·03–0·36) <0·0001
*Adjusted for age, sex, BMI, coronary heart disease, stroke, depression, smoking status, elevated total cholesterol, high 
blood pressure, HbA1c category, use of antihypertensive drugs and statins, and year of procedure. 
Table 3: Eﬀ ect of bariatric surgery on risk of diabetes by age group, sex, BMI, and type of procedure
See Online for appendix
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drawing ﬁ rm conclusions concerning the comparative 
eﬀ ectiveness of diﬀ erent procedures from a non-
randomised study because selection for diﬀ erent proce-
dures might be associated with the underlying risk of 
developing diabetes, and some of the subgroup analyses 
were based on small numbers of outcome events.
Previous studies of bariatric surgery and prevention of 
type 2 diabetes include the SOS study9 and several case 
series (panel).20–22 In the SOS study,9 69% of patients 
underwent vertical banded gastroplasty, 19% underwent 
banding, and 12% received gastric bypass surgery. The 
incidence of diabetes in bariatric surgery patients and 
controls and the relative risk reduction associated with 
bariatric surgery were both very similar to those recorded 
in our study. Our ﬁ ndings, therefore, are important 
conﬁ rmation from a population-based sample that 
intervention with current surgical procedures can reduce 
the incidence of diabetes.
Our study had the strengths of a large population-based 
sample with prolonged follow-up and prospective 
documentation of clinical diabetes in primary care. 
However, we acknowledge several limitations. First, we 
identiﬁ ed three major procedures used in bariatric 
surgery in the UK; however, some surgical techniques are 
done less frequently, such as the duodenal switch, which 
we did not include. Second, controls did not receive 
standardised non-surgical intervention for obesity and, 
during the study period, intensive multimodal weight 
loss programmes in primary care were rare. Third, 
ascertainment of diabetes outcomes was comprehensive, 
and diagnoses noted in CPRD records are generally 
valid.13 However, we were not able to document cases of 
subclinical diabetes that might have been conﬁ rmed by 
testing all patients for evidence of hyperglycaemia. 
We excluded women in whom antidiabetes drugs were 
prescribed for polycystic ovary syndrome, but some other 
prescriptions might have been for diabetes prevention or 
other indications rather than treatment of clinical 
diabetes. Fourth, bodyweight and other relevant measures 
were not recorded consistently during the period of study. 
Preoperative BMI category might have been misclassiﬁ ed 
and we were unable to relate diﬀ erences in diabetes 
incidence to changes in bodyweight, although we should 
point out that the eﬀ ects of bariatric surgery are not 
mediated entirely by changes in bodyweight.23 We noted 
that weight reductions after surgery accorded with those 
of previous reports. Fifth, access to bariatric surgery is 
currently limited in the UK; thus, people receiving 
surgery represent a highly selected group. Sixth, the 
higher prevalence of previous diagnoses of depression in 
surgical patients compared with controls suggests that 
obese individuals with depression were more likely to be 
referred for surgery, possibly with the belief that weight 
loss might improve their depressive symptoms. Seventh, 
patients who received surgery might have been more 
adherent than controls to other diabetes prevention 
advice, including diet or exercise. However, we noted that 
people who received surgery were more likely to be 
prescribed antihypertensive drugs or statins, which can 
sometimes be associated with diabetes. Eighth, controls 
had missing values for blood pressure and plasma 
cholesterol more frequently than did bariatric surgery 
patients, suggesting medical surveillance was decreased 
in this group. Diﬀ erential medical surveillance might 
have made detection of diabetes or prediabetes more 
likely in patients considered for surgery, leading to 
possible exclusion bias in patients receiving surgery. 
However, the higher proportion of bariatric surgery 
patients on antihypertensive or lipid-lowering treatment 
might suggest selection bias in the opposite direction. 
Ninth, we included relevant confounders (such as 
hypertension and hyperlipidaemia) in our analysis, but 
misclassiﬁ cation and missing values could lead to 
residual bias. In a non-randomised study, residual 
confounding from unmeasured genetic, social, or 
environmental variables is a concern. However, we ﬁ tted 
several diﬀ erent models and did sensitivity analyses that 
showed the main ﬁ ndings of the study were robust. 
Finally, nearest neighbour matching gave a comparison 
group that was not exactly matched for key variables. 
Panel: Research in context
Systematic review
We searched Scopus, Web of Science, PubMed, Medline, and 
Embase for studies published in English up to Sept 26, 2014, 
with the keywords: “diabetes”, “bariatric surgery”, 
“prevention”, and “incidence”. We retrieved no randomised 
controlled trials in which the incidence of diabetes after 
bariatric surgery was reported.7 We identiﬁ ed four cohort 
studies in which the development of diabetes after bariatric 
surgery was assessed,9,20–22 none of which were population 
based. The largest cohort was in the Swedish Obese Subjects 
(SOS) study,9 which comprised 1658 participants, with 69% 
receiving vertical banded gastroplasty, 19% gastric banding, 
and 12% gastric bypass from 1987 onwards. Other studies 
were smaller, with fewer than 300 participants; two only 
included people with prediabetes.20,22 All four studies 
suggested reduced occurrence of diabetes after 
bariatric surgery.
Interpretation
In our population-based cohort of 2167 patients who had 
bariatric surgery between 2002 and 2014—including 
laparoscopic adjustable gastric banding, gastric bypass, and 
sleeve gastrectomy—and 2167 controls matched for age, sex, 
and BMI, the incidence of diabetes was reduced after bariatric 
surgery, with an adjusted hazard ratio of 0·20 (95% CI 
0·13–0·30). The association of bariatric surgery with reduced 
diabetes incidence was seen in both men and women, across 
age groups, and after diﬀ erent types of surgical procedure. 
In people with severe obesity, bariatric surgical procedures in 
current use could be eﬀ ective at reducing the incidence of 
clinical diabetes for up to 7 years. 
Articles
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However, covariate adjustment had little eﬀ ect and very 
similar results were obtained when the entire source 
cohort was used for reference. A method of analysis that 
did not allow for matching might give slightly wider CIs 
and larger p values than a matched analysis,24 but our 
results did not raise concerns about statistical error.
Our ﬁ ndings, together with those of previous studies,25 
suggest that bariatric surgery could be a highly eﬀ ective 
method for prevention of diabetes in patients with severe 
obesity. How should surgery for obesity be integrated 
into strategies for control of obesity and prevention of 
diabetes in the population at risk? Further research is 
needed to understand the outcomes of diﬀ erent levels of 
uptake of obesity surgery, and the long-term eﬀ ects for 
patients who receive current surgical procedures for 
obesity.
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